Zai Lab Shares Rise 7.3% on Positive Phase 1 Trial Data
Zai Lab said it reported positive data from a Phase 1 trial evaluating its small cell lung cancer treatment. Shares rose 7.3% in premarket trading to $23.65.
By Adriano MarcheseZai Lab shares rose in premarket trading Friday after the company said that it reported positive data from its phase 1 trial evaluating its small cell lung cancer treatment.Shares rose 7.3% ahead of the morning bell to $23.65.The biopharmaceutical company said Friday that its exp…